

Elizabeth K Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1213170/publications.pdf>

Version: 2024-02-01

16
papers

657
citations

840585

11
h-index

940416

16
g-index

16
all docs

16
docs citations

16
times ranked

972
citing authors

#	ARTICLE	IF	CITATIONS
1	Uterine serous carcinoma: Molecular features, clinical management, and new and future therapies. <i>Gynecologic Oncology</i> , 2021, 160, 322-332.	0.6	23
2	A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer. <i>Nature Communications</i> , 2021, 12, 5574.	5.8	32
3	PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies. <i>Cancers</i> , 2020, 12, 2054.	1.7	43
4	PARP inhibition and immune modulation: scientific rationale and perspectives for the treatment of gynecologic cancers. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094411.	1.4	34
5	Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial. <i>Gynecologic Oncology</i> , 2020, 159, 72-78.	0.6	41
6	Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 957-968.	5.1	140
7	Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 165-188.	1.0	10
8	Combined CDK4/6 and PD-1 Inhibition in Refractory SMARCA4-Deficient Small-Cell Carcinoma of the Ovary, Hypercalcemic Type. <i>JCO Precision Oncology</i> , 2020, 4, 736-742.	1.5	12
9	Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT) Tj ETQq1 1 0.7843 14 rgBI1/Overl	1.4	14
10	Combined PARP and Immune Checkpoint Inhibition in Ovarian Cancer. <i>Trends in Cancer</i> , 2019, 5, 524-528.	3.8	57
11	Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer. <i>Gynecologic Oncology Reports</i> , 2019, 29, 118-122.	0.3	17
12	Antibody-drug conjugates in gynecologic malignancies. <i>Gynecologic Oncology</i> , 2019, 153, 694-702.	0.6	22
13	Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer. <i>Gynecologic Oncology</i> , 2019, 153, 471-478.	0.6	18
14	POLE-mutated clear cell cervical cancer associated with in-utero diethylstilbestrol exposure. <i>Gynecologic Oncology Reports</i> , 2019, 28, 15-17.	0.3	8
15	Primary Care Provider Preferences for Communication with Inpatient Teams: One Size Does Not Fit All. <i>Journal of Hospital Medicine</i> , 2018, 13, 177-178.	0.7	3
16	Endothelial TLR4 activation impairs intestinal microcirculatory perfusion in necrotizing enterocolitis via eNOSâ€“NOâ€“nitrite signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 9451-9456.	3.3	186